Why Most BioPharma Patient Support Programs Are Failing (And What To Do About It)

Published by the Kyand Consulting Team | www.kyand.co

Picture this. A patient just got a life-changing diagnosis. Their doctor hands them a prescription for a medication that could genuinely help. There’s even a “patient support program” attached to it — a whole infrastructure, supposedly, built just for them.

But then? They call the number on the pamphlet. They wait on hold. They fill out forms. They get transferred. They wait some more. Eventually, they give up.

Meanwhile, the biopharma company that funded that program is sitting in a quarterly review, wondering why utilization numbers are so low.

This is happening every single day. And it’s not a mystery — it’s a pattern.

Let’s Be Honest About What’s Going On

Managed Patient Support Services (PSS) represent some of the biggest investments biopharma companies make in the patient journey. We’re talking about Patient Assistance Programs (PAPs), HUB services, digital platforms, prior authorization support — the whole ecosystem. The goal, on paper, is clear: help real people access life-changing medications, survive the nightmare of insurance navigation, and actually stay on treatment long enough to benefit.

The intention? Real. The spending? Absolutely real.

The results? Often… not so much.

If you’ve been searching around for clarity on managed patient support services biopharma mistakes, you’ve landed in the right place. At Kyand, we work directly with life sciences companies to close the gap between what these programs promise and what they actually deliver. And what we see repeatedly — across companies big and small — is a handful of very fixable failures that keep undermining everything.

Here’s what’s actually going wrong.

First, the Scale of the Problem (It’s Big)

Non-adherence alone causes 50% of all treatment failures. Fifty percent. And it contributes to hundreds of billions in avoidable healthcare costs every year.

Patient support programs exist, in large part, to fix this. Yet low utilization, regulatory violations, and genuinely bad patient experiences keep plaguing the industry.

Here’s the thing — these failures aren’t random accidents. They follow patterns. Operational patterns. Ethical ones. Regulatory ones. Design ones. And once you can see them clearly, you also start to see how fixable they actually are.

So let’s go through them.

Mistake #1: Still Running Things on Spreadsheets in 2025

I know. It sounds basic. But you’d be surprised.

A lot of biopharma companies are still managing patient support through spreadsheets, disconnected data systems, and manual entry workflows. Patient Services Managers (PSMs) — the actual humans trying to help patients — spend huge chunks of their day piecing together fragmented records instead of doing what they were hired to do: educate, engage, and support.

The downstream effects stack up fast. Prior authorization workflows get jammed. Treatment gets delayed. And in therapeutic areas like oncology, rare disease, or autoimmune conditions, delays aren’t just inconvenient — they carry real clinical risk.

Courier Health puts it plainly: “heavy reliance on manual processes results in wasted resources, which can be highly costly.” And yet, automation tools that could clear these bottlenecks are still chronically underused across the industry.

This isn’t really a technology gap. It’s a priorities gap.

Companies that treat automation as a “nice to have” instead of foundational infrastructure will keep watching their PSMs burn out, their patients slip through the cracks, and their program ROI disappoint everyone in the room.

Mistake #2: Treating Compliance Like It’s Someone Else’s Problem

Patient support programs don’t operate in a simple regulatory environment. Not even close.

We’re talking about the Anti-Kickback Statute, the False Claims Act, HIPAA, CCPA, and a constantly shifting patchwork of state-level rules. Getting any of this wrong isn’t just a paperwork headache — it’s potentially an existential threat to the business.

And it’s not slowing down. The 2025 HIPAA updates brought new mandatory requirements around data governance and partner certification. A lot of biopharma companies are stepping into this new environment without completed gap analyses, without solid data frameworks, and without confirming that their third-party HUB vendors are even certified to the updated standards.

But here’s the part that doesn’t get talked about enough — the pharmacovigilance problem.

The DIA Global Forum has flagged a structural flaw that should make every patient support leader uncomfortable: many PAPs — we’re talking 2,000+ active programs across 500+ companies — are run by marketing or medical affairs teams with little to no pharmacovigilance input. Adverse events collected through patient interactions? Frequently undocumented, misrouted, or never reported on time.

That’s not just a compliance gap. That’s a patient safety gap.

Mistake #3: Calling It Patient Support When It’s Really Brand Marketing

Okay. This one’s uncomfortable. But it needs to be said.

There’s a long-running critique — and honestly, a well-supported one — that many manufacturer assistance programs are less about patient access and more about building brand loyalty, enabling premium pricing, and generating warm PR.

Investigative reporting in the LA Times described manufacturer assistance programs as a “triple boon”: they drive demand, they justify higher list prices, and they look great in press releases. Health economist David Howard at Emory framed it with brutal clarity — manufacturers effectively pay a $25 co-pay subsidy to sell a $50,000-per-year drug. Great math for the manufacturer. Not so great for the healthcare system.

STAT News in 2025 went after the patient advocacy angle too, reporting on executives who privately view patient stories as “misery porn” — emotionally compelling content assets for patient-centric brand strategy — while the programs doing the heavy lifting deliver pretty limited real-world benefit.

It’s worth noting that Medicare straight-up prohibits direct manufacturer co-pay assistance because of these kickback dynamics. Commercial patients, though? Still enrolled in programs designed around retention and volume — not purely around what they need.

The consequence is real: short-term savings during commercial coverage, followed by a cliff when patients transition to Medicare and suddenly have no options left.

Mistake #4: Building Programs Too Complicated to Actually Use

Here’s a simple test. If a patient — dealing with a serious diagnosis, financial stress, and a complex care team — can’t figure out how to use your support program, it’s not a support program. It’s a liability disclaimer dressed up as one.

BioPharma Dive has identified three compounding barriers that keep showing up. First, low awareness — patients and providers often have no idea the program even exists. Second, provider bandwidth — understaffed practices don’t have time to enroll patients, verify benefits, or train staff on yet another tool. Third, outdated delivery — in a world where 80% of patients prefer digital access, plenty of programs still rely on phone trees and paper forms that feel like calling a bank in 1998.

Pharmaceutical Executive describes the post-prescription experience for many patients as hitting a wall. Delays. Denials. Confusing insurance letters. No clear guidance on what to do next.

For someone managing a complex chronic condition — juggling cognitive fatigue, financial pressure, and multiple specialists — that friction isn’t just annoying. It’s a reason to stop trying.

Mistake #5: Assuming All Patients Need the Same Thing

This one’s sneaky because it often comes from a genuine place. Companies design programs based on what they think patients need — based on internal expertise, past programs, market research. And then they’re confused when uptake is low.

The problem is that assumptions aren’t the same as understanding.

Courier Health makes an important distinction here: internal patient support teams, when properly resourced, tend to outperform external HUB vendors because they build deeper, more direct relationships with patients. Yet many companies outsource everything to HUBs, build programs on outdated assumptions, and then scratch their heads at the numbers.

And for patients with chronic conditions being managed across multiple providers? A fragmented support model isn’t just inefficient. Without real coordination, medication errors and gaps in care become predictable outcomes.

Mistake #6: Pulling Clinical Guidance Out of the Support Model

This might be the most consequential mistake. And ironically, it’s one of the least discussed.

Pharmaceutical Executive has reported on what happens when patients can’t access one-on-one clinical support: they can’t navigate PBM complexity, can’t identify cost-reduction options, don’t understand their benefits, and aren’t prepared to recognize or report side effects. In a world where alternative sourcing platforms and compounding pharmacies are increasingly part of the mix, that guidance gap has real safety implications.

And then there’s the pharmacovigilance angle again. The DIA Global Forum has documented how PAPs designed without safety reporting integration become black holes for adverse event data. Support staff collecting patient information during routine interactions — nurses, vendor reps, care coordinators — may have zero protocol for routing safety concerns to the pharmacovigilance team on time. Cases involving vendor delays or system outages have directly compromised data integrity.

Mistake #7: Ignoring What Industry-Funded Advocacy Actually Looks Like From the Outside

This one’s bigger than any single program. It’s about the whole ecosystem.

STAT News has reported on how millions in manufacturer funding flow to patient advocacy organizations — with outcomes that often serve brand visibility more than actual patient interests. In the rare disease space, where manufacturer-advocacy relationships are especially intense, the criticism has been particularly sharp. Researchers use the phrase “corporate capture” to describe what happens when advocacy organizations start representing manufacturer interests more than the patients they’re supposed to speak for.

PMC/NIH research has also raised flags about how physician-industry relationships within patient support ecosystems can erode the physician-patient trust relationship when financial incentives aren’t carefully disclosed and managed.

The downstream effect? Patients, physicians, and payers are increasingly skeptical of industry-funded support programs. That skepticism translates directly into underutilization. Trust is genuinely hard to rebuild once it’s gone.

What Happens When These Mistakes Stack Up

They don’t stay separate. They compound.

When manual processes slow everything down, compliance gets missed. When compliance is an afterthought, adverse events go unreported. When programs are too complex to use, patients abandon treatment. When marketing is dressed up as patient aid, trust erodes. And then the whole thing stops working — for patients and for the business.

The measurable results are pretty grim:

• Low utilization despite massive investment
• Regulatory fines and settlements that hurt both finances and reputation
• Adverse event underreporting creating patient safety risk
• Treatment abandonment undermining clinical and commercial outcomes
• Erosion of trust with the exact people the program is supposed to serve

The companies that are doing this well have made a real strategic choice: they treat patient support as an integrated clinical, commercial, and compliance function — not a marketing activation or a cost center to be managed down.

So What Does Good Actually Look Like?

Based on the evidence above and the day-to-day work we do at Kyand, here’s what effective managed patient support services look like in practice:

• Automation and integration — Centralized platforms that eliminate manual bottlenecks, surface real-time patient insights, and enable proactive outreach
• Compliance by design — Legal, regulatory, and pharmacovigilance in the room from inception; ongoing gap analyses; rigorous vendor management
• User-first experience — Digital-first access, simple enrollment, and patient journeys designed with the same care as consumer products
• Real personalization — Segmentation based on actual barriers, not assumptions; tiered support that adjusts to individual need
• Clinical integration — Nurses, pharmacists, and care coordinators embedded in the model with full patient context
• Ethical alignment — Transparent funding, genuinely patient-centric objectives, and the backbone to prioritize outcomes over brand metrics

One Last Thing

Patient support programs represent a real opportunity — to improve lives, build genuine trust, and show that biopharma can be a meaningful partner in healthcare instead of just a vendor.

Most companies say they want that. Fewer have built programs that actually deliver it.

The mistakes here aren’t inevitable. They come from underinvestment, misaligned incentives, siloed thinking, and — honestly, sometimes — a lack of genuine commitment to patient outcomes when they conflict with short-term commercial goals.

That can change. The companies making different choices right now are the ones that’ll look very different in five years.

Sources referenced include analysis from Courier Health, PatientPartner, BioPharma Dive, Pharmaceutical Executive, STAT News, the DIA Global Forum, LA Times investigative reporting, and peer-reviewed research from PMC/NIH. Data and regulatory references reflect findings from 2015–2025.